Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels
- PMID: 11878818
- DOI: 10.1006/exer.2001.1098
Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels
Abstract
The major problems associated with the use of corticosteroids for the treatment of ocular diseases are their poor intraocular penetration to the posterior segment when administered locally and their secondary side effects when given systemically. To circumvent these problems more efficient methods and techniques of local delivery are being developed. The purposes of this study were: (1) to investigate the pharmacokinetics of intraocular penetration of hemisuccinate methyl prednisolone (HMP) after its delivery using the transscleral Coulomb controlled iontophoresis (CCI) system applied to the eye or after intravenous (i.v.) injection in the rabbit, (2) to test the safety of the CCI system for the treated eyes and (3) to compare the pharmacokinetic profiles of HMP intraocular distribution after CCI delivery to i.v. injection. For each parameter evaluated, six rabbit eyes were used. For the CCI system, two concentrations of HMP (62.5 and 150mg ml(-1)), various intensities of current and duration of treatment were analyzed. In rabbits serving as controls the HMP was infused in the CCI device but without applied electric current. For the i.v. delivery, HMP at 10mg kg(-1)as a 62.5mg ml(-1)solution was used. The rabbits were observed clinically for evidence of ocular toxicity. At various time points after the administration of drug, rabbits were killed and intraocular fluids and tissues were sampled for methylprednisolone (MP) concentrations by high pressure liquid chromatography (HPLC). Histology examinations were performed on six eyes of each group. Among groups that received CCI, the concentrations of MP increased in all ocular tissues and fluids in relation to the intensities of current used (0.4, 1.0 and 2.0mA/0.5cm(2)) and its duration (4 and 10min). Sustained and highest levels of MP were achieved in the choroid and the retina of rabbit eyes treated with the highest current and 10min duration of CCI. No clinical toxicity or histological lesions were observed following CCI. Negligible amounts of MP were found in ocular tissues in the CCI control group without application of current. Compared to i.v. administration, CCI achieved higher and more sustained tissue concentrations with negligible systemic absorption. These data demonstrate that high levels of MP can be safely achieved in intraocular tissues and fluids of the rabbit eye, using CCI. With this system, intraocular tissues levels of MP are higher than those achieved after i.v. injection. Furthermore, if needed, the drug levels achieved with CCI can be modulated as a function of current intensity and duration of treatment. CCI could therefore be used as an alternative method for the delivery of high levels of MP to the intraocular tissues of both the anterior and posterior segments.
Copyright 2002 Elsevier Science Ltd.
Similar articles
-
Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration.Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3299-306. Invest Ophthalmol Vis Sci. 2002. PMID: 12356838
-
Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma.Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3644-9. doi: 10.1167/iovs.04-0228. Invest Ophthalmol Vis Sci. 2004. PMID: 15452072
-
Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats.Exp Eye Res. 1997 Oct;65(4):533-45. doi: 10.1006/exer.1997.0364. Exp Eye Res. 1997. PMID: 9464186
-
Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.Adv Drug Deliv Rev. 2005 Dec 13;57(14):2063-79. doi: 10.1016/j.addr.2005.08.006. Epub 2005 Nov 28. Adv Drug Deliv Rev. 2005. PMID: 16310884 Review.
-
Iontophoresis: a non-invasive ocular drug delivery.J Control Release. 2006 Feb 21;110(3):479-89. doi: 10.1016/j.jconrel.2005.09.049. Epub 2005 Dec 15. J Control Release. 2006. PMID: 16343678 Review.
Cited by
-
Non-Invasive Iontophoretic Delivery of Cytochrome c to the Posterior Segment and Determination of Its Ocular Biodistribution.Pharmaceutics. 2022 Aug 31;14(9):1832. doi: 10.3390/pharmaceutics14091832. Pharmaceutics. 2022. PMID: 36145581 Free PMC article.
-
Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging.Int J Pharm. 2007 Apr 20;335(1-2):46-53. doi: 10.1016/j.ijpharm.2006.11.001. Epub 2006 Nov 3. Int J Pharm. 2007. PMID: 17236728 Free PMC article.
-
Early effects of corneal collagen cross-linking by iontophoresis in ex vivo human corneas.Graefes Arch Clin Exp Ophthalmol. 2015 Feb;253(2):277-86. doi: 10.1007/s00417-014-2836-7. Epub 2014 Nov 4. Graefes Arch Clin Exp Ophthalmol. 2015. PMID: 25363654
-
Innovative Strategies for Drug Delivery to the Ocular Posterior Segment.Pharmaceutics. 2023 Jul 1;15(7):1862. doi: 10.3390/pharmaceutics15071862. Pharmaceutics. 2023. PMID: 37514050 Free PMC article. Review.
-
Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle.J Control Release. 2018 May 10;277:14-22. doi: 10.1016/j.jconrel.2018.03.001. Epub 2018 Mar 2. J Control Release. 2018. PMID: 29505807 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical